Mesenchymal Stem Cells and Their Secretome: Candidates for Safe and Effective Therapy for Systemic Lupus Erythematosus

The document discussed the potential of mesenchymal stem cells (MSCs) and their secretome as promising therapeutic tools for systemic lupus erythematosus (SLE), an autoimmune disorder with elusive pathogenesis. Current treatments only offer disease remission, highlighting the need for more effective and safer options. MSCs, particularly those from perinatal tissues like Wharton's jelly, were noted for their unique immunomodulatory properties and low immunogenicity. They exert effects through direct communication and paracrine actions, suggesting that MSC secretome could be a standalone therapy. While not yet applied to SLE, MSC secretome showed efficacy in other diseases, indicating potential for reducing SLE symptoms and maintaining remission.